Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Blood
; 135(18): 1517-1530, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107537
3.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer
; 19(1): 504, 2019 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31138244
4.
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Am J Hematol
; 96(7): E253-E257, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844864
5.
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Biol Blood Marrow Transplant
; 19(3): 398-404, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23078786
6.
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Cells
; 9(2)2020 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32013131
7.
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Theranostics
; 10(6): 2645-2658, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32194826
8.
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Clin Lymphoma Myeloma Leuk
; 18(11): e493-e499, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30104177
9.
Living with the burden of relapse in multiple myeloma from the patient and physician perspective.
Leuk Res
; 59: 75-84, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28582636